Denali Therapeutics Inc.
NASDAQ:DNLIBiotechnology
+$0.09 today
- Market cap
- $2.92B
- Beta
- 1.01
- P/E (TTM)
- -8.7
- EPS (TTM)
- -$2.72
Volume 1.27M
Average 1.84M
Returns on capital
Denali Therapeutics Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-50.6%
avg -14.2%
ROIC
-52.6%
avg -28.7%
ROA
-44.8%
avg -24.0%
Analysis
ROA is currently the strongest return metric at -44.8% versus its period average of -24.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Ryan J. Watts | Co-Founder, President, Chief Executive Officer & Director | USD 1.42M | 50 | 2.12M | 1.34% |
Alexander O. Schuth | Co-Founder, Chief Financial Officer, Chief Operating Officer & Secretary | USD 926.18K | 53 | 279.00K | 0.18% |
Chris Walsh | General Counsel | — | — | — | — |
Joe Lewcock | Chief Scientific Officer | — | — | — | — |
Cindy Dunkle | Chief People Officer | — | — | — | — |
Katie Peng | Chief Commercial Officer | — | 55 | — | — |
Dana Andersen | Chief Technical and Manufacturing Officer | — | — | — | — |
Peter Chin | Acting Chief Medical Officer & Head of Development | — | 58 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 1, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$22,857.14
Sells
7
$1.30M
Net Transaction Value
−$1.28M
Net selling
Most Active
Schuth Alexander O.
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 4, 26Sep 4, 2026 | Chin Peter Scott Direct | Sell | $36.9K$36,867.66 |
| Sep 2, 26Sep 2, 2026 | Thornberry Nancy Direct | Sell | $247.3K$247,328.40 |
| Sep 2, 26Sep 2, 2026 | Thornberry Nancy Direct | Sell | $14.6K$14,600.10 |
| Sep 1, 26Sep 1, 2026 | Schuth Alexander O. Direct | Sell | $64.9K$64,881.92 |
| Aug 11, 26Aug 11, 2026 | Schuth Alexander O. Direct | Sell | $71.6K$71,624.99 |
| Jan 6, 26Jan 6, 2026 | Watts Ryan J. Direct | Sell | $580.8K$580,767.00 |
| Jan 6, 26Jan 6, 2026 | Schuth Alexander O. Direct | Sell | $284.1K$284,097.00 |
| Dec 11, 25Dec 11, 2025 | BAKER BROS. ADVISORS LP Indirect | Buy | $21K$20,951.91 |
| Dec 11, 25Dec 11, 2025 | BAKER BROS. ADVISORS LP Indirect | Buy | $1.9K$1,905.23 |
Summary
Insiders reported 2 buys worth $22,857.14 and 7 sells worth $1.30M over the last 12 months. That adds up to net selling of $1.28M. Schuth Alexander O. was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A14 analysts |
| Net Income | N/A | N/A | N/A | N/A14 analysts |
| EBIT | N/A | N/A | N/A | N/A14 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Denali Therapeutics Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about DNLI's management, answered from reported figures.
Who manages DNLI?
Denali Therapeutics Inc. (DNLI) lists 8 active executives. The top listed executive is Alexander O. Schuth, Co-Founder, Chief Financial Officer, Chief Operating Officer & Secretary.
Are DNLI insiders buying or selling?
Recent insider activity shows net buying of $16.43M.
Continue the stock analysis
Jump to another research area for this company.